COMMUNIQUÉS West-GlobeNewswire

-
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
14/10/2024 -
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
14/10/2024 -
Novo Nordisk A/S - share repurchase programme
14/10/2024 -
Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek
14/10/2024 -
NewGenIvf Receives Nasdaq Notification Regarding Minimum Bid Price
14/10/2024 -
Sharps Technology, Inc. Announces Stockholders’ Approval of Reverse Stock Split Ratio and Effective Date
14/10/2024 -
Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024
14/10/2024 -
HeartFlow to Present Latest Data on AI-Enabled Coronary Artery Disease Management at TCT 2024
14/10/2024 -
Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
14/10/2024 -
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
14/10/2024 -
Boundless Bio Announces Departure of Chief Financial Officer
14/10/2024 -
MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6
14/10/2024 -
Helio Genomics’ Methylation Model Score for Assessing Prognosis and Treatment Response in Patients with Hepatocellular Carcinoma Presented as Top Abstract at the 2024 San Antonio Liver Cancer Symposium
14/10/2024 -
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
14/10/2024 -
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
14/10/2024 -
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
14/10/2024 -
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
14/10/2024 -
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
12/10/2024 -
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
11/10/2024
Pages